Exubera - approvable is no longer reimbursable
October 24, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Exubera is the first major product to fail primarily due to Pfizer's inability to convince payors of it's value for money There is now significant additional risk in achieving market access after regulatory approval. Pricing and reimbursement decisions will play an increasingly important role in the commercial success of companies going forward.
Page : 11 to 1 of 1
February 7, 2012
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
Medtech M&A activity accelerates in 2011
November 30, 2011